Relationship between lncRNA-Ang362 and prognosis of patients with coronary heart disease after percutaneous coronary intervention

Abstract

The severity and complexity evaluation of coronary artery disease in patients with coronary heart disease (CHD) require objective and accurate prognosis indexes. We assessed the relationship between lncRNA-Ang362 and prognosis of CHD patients after percutaneous coronary intervention (PCI). Clinical follow-up data of CHD patients were prospectively collected. LncRNA-Ang362 levels were detected by real-time quantitative polymerase chain reaction. Survival rate was calculated by the Kaplan-Meier method, and risk ratios and 95% confidence intervals were computed using univariate and multivariate COX proportional hazard models. Finally, 434 patients were included in the follow-up cohort. The median follow-up time was 24.8 months (6.7-40). The incidence of adverse cardiovascular events was 13.6%. The high expression group significantly tended to be smoker and higher body mass index, low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, creatinine, and uric acid levels compared with the low expression group. According to the SYNTAX grade, the high-risk and medium-risk groups had significantly higher lncRNA expression levels than the low-risk group. The univariate COX regression analysis indicated that high lncRAN-Ang362 expression significantly increased the risk of adverse cardiovascular events in CHD patients after PCI (hazard risk (HR)=3.19, 95%Confidence interval (CI): 1.29-7.92). Multivariate analysis found high lncRNA-Ang362 expression was independently related to worse prognosis in CHD patients after PCI (HR=2.83, 95%CI: 1.34-6.02). Plasma lncRNA-Ang362 may be a prognosis factor in CHD patients after PCI. The patients with higher lncRNA-Ang362 expression usually have poor prognosis.

Effect of different doses of atorvastatin on collateral formation in coronary artery disease patients with coronary atherosclerosis

“…CAD has a relatively high morbidity and mortality, posing a severe threat to human health, and increases the burden of the family and society. Currently, commonly, surgical treatment and pharmacotherapy are used clinically; among them, surgical treatment has a higher requirement of tolerance by the patients and readily induce vessel nerve reflex, and some patients are not satisfied with treatment efficacy [8]. The development of CAD is closely associated with blood lipid levels.…”

Correlation of Long Non-coding RNA LncRNA-FA2H-2 With Inflammatory Markers in the Peripheral Blood of Patients With Coronary Heart Disease

“…In addition, LncRNA CARMEN and LncRNA fendrr are associated with embryonic heart development ( 18 , 19 ). LncRNA-Ang362 may be associated with prognosis after coronary stenting (percutaneous coronary intervention) for CHD ( 20 ). Increased expression of LncRNA GAS5 was found in plaques of atherosclerotic individuals, and the mechanism may be related to exosome regulation of macrophage and endothelial cell apoptosis in atherosclerotic plaques ( 21 ).…”

Knockdown of mesenchymal stem cell‑derived exosomal LOC100129516 suppresses the symptoms of atherosclerosis via upregulation of the PPARγ/LXRα/ABCA1 signaling pathway

“…Exosomes derived from MSCs carry a number of bioactive substances, such as proteins, miRNAs and lncRNAs, and play an important role in the treatment of cardiovascular diseases, such as atherosclerosis ( 18 , 43 , 44 ). A high expression level of lncRNA-Ang362 was shown to lead to a poor prognosis in patients with CAD ( 45 ). Moreover, Mao et al ( 46 ) demonstrated that MSC-derived exosomal lncRNA Krüppel-like factor 3 antisense RNA 1 alleviated the development of myocardial infarction via the miR-138-5p/Sirtuin-1 axis ( 46 ).…”